相关实验视频

Updated: Sep 19, 2025

Isolation of Primary Mouse Hepatocytes for Nascent Protein Synthesis Analysis by Non-radioactive L-azidohomoalanine Labeling Method

Isolation of Primary Mouse Hepatocytes for Nascent Protein Synthesis Analysis by Non-radioactive L-azidohomoalanine Labeling Method

Published on: October 23, 2018

关于GLP1作用与代谢性肝病之间的相关性的遗传分析:从孟德尔随机化分析的见解

Zhiqiang Ma¹, Binyu Wang¹, Danpei Li^2,3

¹Division of Cardiology, Department of Internal Medicine, Liyuan Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.

Journal of diabetes investigation

|June 2, 2025

概括

基因分析表明,葡萄糖类1 (GLP1) 的作用可能会因果性地降低与代谢功能障碍相关的脂肪性肝病 (MASLD) 的风险. 这支持GLP1.

科学领域:

遗传学和分子生物学
代谢障碍代谢障碍代谢障碍
肝病学肝病学是一种肝病学.

背景情况:

与代谢功能障碍相关的脂肪性肝病 (MASLD) 是一个日益严重的健康问题,治疗选择有限.
葡萄糖类1 (GLP1) 受体激动剂对MASLD有希望,但强有力的遗传证据很少.

研究的目的:

使用遗传方法研究GLP1作用和MASLD之间的潜在因果关系.
探索GLP1-MASLD协会中常见的MASLD风险因素的调解作用.

主要方法:

门德尔随机化 (MR) 分析利用cis-eQTL和误解突变作为GLP1作用的遗传代理.
基于FinnGen队列数据的初级分析,在独立队列中进行复制.
调解分析和全现象关联研究 (Phe-WAS) 以评估风险因素和更广泛的影响.

主要成果:

基因预测的GLP1作用,由cis-eQTLs代理,与降低的MASLD风险显著相关 (OR:0.36,P=1.37E-22).
调解分析显示GLP1对2型糖尿病 (6%) 和高血压 (4%) 的MASLD风险的影响显著,尽管很小.
使用误解突变没有发现因果关系;Phe-WAS表明GLP1作用对心血管和脏有好处.

结论:

遗传证据支持GLP1作用在降低MASLD风险方面的潜在因果作用.
GLP1的作用可能会给肝脏健康带来好处,包括心血管和脏保护.

关键词:

在 GLP1 中,GLP1 是 GLP1 的代名词.马斯尔德马斯尔德是什么意思门德尔的随机化

更多相关视频

Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution

Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution

Published on: April 16, 2019

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro

Published on: January 31, 2022

相关概念视频

Genome-wide Association Studies-GWAS

Genome-wide Association Studies-GWAS

Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...

Glucagon-like Receptor Agonists

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...